
这不是一个适合现在进入的市场。 盘面已经明显偏向价格战:新品里只有33.33%能赚钱,66.67%不赚钱;而且新品牌只有11个,虽然没到30个以上的“全面过热”阈值,但失败样本已经非常集中,说明同质化和竞争压迫已经很重,尤其对小品牌不友好。
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
这个市场不适合进入:新品盈利率只有37.5%,但新品亏损率高达62.5%,而且你这条线里已经出现了明显的价格竞争和“靠强推才能活”的迹象。用户预算50万人民币表面上够覆盖入场,但只能算够做单个ASIN的前期铺货和投放,不够证明长期能打赢。
Some categories may not originally require certain certificates for entry; however, some products may target specific features (e.g. Bluetooth) or customers (e.g. children), and additional certificates may be required in the target marketplace (e.g. FCC, CPC).
Alternative solutions may pose a risk to your investment in certain markets.
这个市场可以进入,但只适合有明确差异化的品牌;如果只是做基础液体B族,已经明显接近价格战区,不适合盲目上。 关键信号是:市场里新品牌持续出现,但成功并不普遍,真正能跑通的案例都在“高配方、液体剂型、功能更强”的方向上,而不是普通同质化产品。
结论很明确:这个市场不适合现在进入,属于明显的高压竞争区,尤其对小品牌不友好。 新品里能稳定赚钱的比例只有33.33%,但真正达到你要求的“够健康、够安全”的利润结构并不漂亮;更关键的是,新品中66.67%都不赚钱,说明新品失败远多于成功,市场已经在靠强品牌和重投放硬撑。
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
This are the profit ratios of all new products. There are products without sufficient sales, no more than 100pcs in 3 months, or no profit ratio data, or just released. Those will be considered as 'other'
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
![]() | B0D6NP5SN5 | NUSAVA | 2024-08-22 | Yes | $24.95 | 3000pcs | $74850.0 | 31.71% | $23734.94 |
![]() | B0F4RQJNJS | NUSAVA | 2025-04-14 | Yes | $27.67 | 2000pcs | $55340.0 | 33.07% | $18300.94 |
![]() | B0DFB17P3W | NUSAVA | 2024-08-27 | Yes | $24.95 | 2000pcs | $49900.0 | 31.09% | $15513.91 |
![]() | B0DFGHSG1N | NUSAVA | 2024-08-28 | Yes | $24.95 | 1000pcs | $24950.0 | 31.08% | $7754.46 |
![]() | B0FCH1W1PT | NUSAVA | 2025-10-10 | Yes | $23.53 | 1000pcs | $23530.0 | 32.79% | $7715.49 |
![]() | B08221NY2L | NutraChamps | 2019-11-26 | Yes | $22.42 | 1000pcs | $22420.0 | 34.14% | $7654.19 |
![]() | B09M9827JJ | Why Not Natural | 2022-04-28 | Yes | $22.89 | 1000pcs | $22890.0 | 32.61% | $7464.43 |
![]() | B0FSKFTZ6R | iMATCHME | 2025-09-25 | Yes | $23.99 | 400pcs | $9596.0 | 33.25% | $3190.67 |
![]() | B0FPF7ZF32 | Vita PLynxera | 2025-09-02 | Yes | $19.99 | 300pcs | $5997.0 | 29.79% | $1786.51 |
![]() | B0C1FS3214 | Doctor Danielle | 2023-04-04 | Yes | $24.99 | 200pcs | $4998.0 | 35.72% | $1785.29 |
![]() | B0GT3JHKZ4 | Newpie | 2026-03-28 | Yes | $20.46 | 250pcs | $5115.0 | 30.39% | $1554.45 |
![]() | B00FZNC3QG | B Total | 2014-02-12 | Yes | $15.42 | 300pcs | $4626.0 | 23.23% | $1074.62 |
![]() | B0F3CXHL33 | GREENPEOPLE | 2025-07-02 | Yes | $26.95 | 100pcs | $2695.0 | 32.92% | $887.2 |
![]() | B0FX19817R | Codeage | 2025-10-19 | Yes | $24.99 | 100pcs | $2499.0 | 35.18% | $879.15 |
![]() | B005PXYX0U | Quantum Nutrition | 2011-08-19 | Yes | $39.35 | 50pcs | $1967.5 | 40.39% | $794.68 |
![]() | B0GS8J3ZXQ | SIZRCSM | 2026-03-12 | Yes | $24.62 | 100pcs | $2462.0 | 31.51% | $775.78 |
![]() | B0DJDL6HH1 | Tropical Oasis | 2024-10-02 | Yes | $23.43 | 100pcs | $2343.0 | 32.88% | $770.38 |
![]() | B0DK97HCK8 | CFILIHTC | 2024-11-30 | Yes | $19.99 | 100pcs | $1999.0 | 29.65% | $592.71 |
![]() | B0G2TH6FX7 | NEW AGE | 2025-11-18 | Yes | $29.95 | 50pcs | $1497.5 | 37.23% | $557.52 |
![]() | B07N7GQPN9 | Zoomavit | 2019-05-22 | Yes | $25.72 | 50pcs | $1286.0 | 36.32% | $467.08 |
Most profitable new products ranked by profit value. Only includes newly released products with positive profitability and active sales.
![]() | B0FCH1W1PT | NUSAVA | 2025-10-10 | Yes | $23.53 | 1000pcs | $23530.0 | 32.79% | $7715.49 |
![]() | B0FSKFTZ6R | iMATCHME | 2025-09-25 | Yes | $23.99 | 400pcs | $9596.0 | 33.25% | $3190.67 |
![]() | B0FPF7ZF32 | Vita PLynxera | 2025-09-02 | Yes | $19.99 | 300pcs | $5997.0 | 29.79% | $1786.51 |
![]() | B0GT3JHKZ4 | Newpie | 2026-03-28 | Yes | $20.46 | 250pcs | $5115.0 | 30.39% | $1554.45 |
![]() | B0FX19817R | Codeage | 2025-10-19 | Yes | $24.99 | 100pcs | $2499.0 | 35.18% | $879.15 |
![]() | B0GS8J3ZXQ | SIZRCSM | 2026-03-12 | Yes | $24.62 | 100pcs | $2462.0 | 31.51% | $775.78 |
![]() | B0G2TH6FX7 | NEW AGE | 2025-11-18 | Yes | $29.95 | 50pcs | $1497.5 | 37.23% | $557.52 |
![]() | B0H1R3N1NV | YLXYZUAD | 2026-05-14 | Yes | $10.5 | 300pcs | $3150.0 | 12.29% | $387.14 |
这个市场不值得进入,原因很直接:新品牌成功率只有33.33%,但失败率高达66.67%,而且新产品整体盈利率只有33.33%;更关键的是,当前样本里已经出现明显的价格战和高竞争信号,低价产品与低利润产品并存,整体不是一个适合稳健进入的市场。
从证据看,市场样本里可见总收入约为349,847.5美元,但这并不代表好做,而是说明头部产品还能吃到销售;真正的问题是,新产品里只有8个盈利、16个不盈利,失败面是成功面的2倍。新品牌里虽然有6个真实盈利案例,但大多靠液体滴剂+甲基化B族+差异化功能组合,例如 Newpie 的 B0GT3JHKZ4、Codeage 的 B0FX19817R、iMATCHME 的 B0FSKFTZ6R、SIZRCSM 的 B0GS8J3ZXQ、YLXYZUAD 的 B0H1R3N1NV,单个样本月利润大致在387到3,190美元之间;但与此同时,NEW AGE、JUIWEFKK、AuraraNeNourish、NUSAVA 等品牌也有多个失败ASIN,说明新人不是随便做就能赢,必须明显差异化,并且预算不能只按前期上架算,还要预留研发、包装和品牌成本。
What is the ratio of profitable products
What is the ratio of different brands owning all profitable new products
What is the ratio of different brands owning all nonprofitable new products
结论很明确:这个市场不值得进入,已经进入高压竞争区,且对新品牌和小商家都不友好。 近两年新品牌释放的新品里,盈利只占37.5%,未盈利占62.5%;按时间看,2025年到2026年新入场持续增加,但赚钱结果没有同步改善,反而更多集中在“其他失败项”里,说明竞争在加剧而不是变轻松。
证据也很直接:最新成功样本大多不是“真小品牌”稳定跑出来的,而是靠较重预算和成熟打法。 新品牌里能赚钱的只有6个样本,分别是 iMATCHME 的 B0FSKFTZ6R(约33.25%利润率,月销400,月营收约95.96万美金)、SIZRCSM 的 B0GS8J3ZXQ(约31.51%利润率,月销100)、Newpie 的 B0GT3JHKZ4、YLXYZUAD 的 B0H1R3N1NV、Codeage 的 B0FX19817R、NEW AGE 的 B0G2TH6FX7;但失败样本有10个,集中在 NEW AGE、JUIWEFKK、duwhot、Aube'Azur、iMATCHME、Newpie、NUSAVA、GREENPEOPLE 等品牌。特别是 duwhot 的 B0FQHWN9HP、B0G3NNCC7F 这类只有30来个评价却没跑通,说明不是靠低门槛就能复制成功。市场里真正稳的老品牌是 NUSAVA:B0D6NP5SN5、B0F4RQJNJS、B0DFB17P3W 都在31%~33%利润率、月销2000~3000;但这属于老品牌强势盘,不应当拿来当小商家参考。按你的预算,单个新品进入门槛约在 1,261.78~1,578.16 美金,看似不高,但这只是早期进场、没覆盖研发、品牌和认证的成本;结合当前胜率和品牌分布,实际进入难度远高于这个数字。
短结论:不建议继续推进。 对大品牌,这里也只是“有条件可打”,但要接受高预算、强投放、强品牌和持续研发;对小商家,更没有稳定可复制的成功路径。要么避开,要么只考虑极强差异化产品,否则很容易陷入价格战和低胜率消耗。
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 1 | 0 | 0 | 1 | 4 | 0 | 9 |
| 2026 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 6 |
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2025/7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| 2025/9 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 3 |
| 2025/10 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| 2025/11 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| 2025/12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| 2026/1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| 2026/3 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 |
| 2026/4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| 2026/5 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 2026/6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |